Singapore, June 14, 2010: The third edition of BioSpectrum Asia Pacific Survey 2010 is an effort to give a rounded view of the progress the life sciences industry has made. According to the survey,in 2009, Sinopharm has registered an impressive 23.18 percent growth year-over-year, accumulating a revenue of $6.88 billion as against $5.58 billion in 2008.

Rank: 1
Company: Sinopharm Group
Revenue: $6.88 bn
Chairman: Mr She Lulin
Business: R&D, manufacturing and distribution of medicine and other healthcare products
Website: www.sinopharm.com
Startup Year: 1998
Country: China 

Clocking $6.8 billion in revenues for 2009, Sinopharm Group has made it to the number one slot of the Top 20 list compiled by BioSpectrum. Sinopharm is the largest pharmaceutical company in China, jointly-owned by China National Pharmaceutical Group and Shanghai Fosun Pharmaceutical.

The company is directly controlled by the State-owned Assets Supervision and Administration Commission of the State Council (SASAC). During the 2009 outbreak of H1N1 influenza, Sinopharm acted promptly and carried out a series of activities of research and development, production, emergency storage and supply for H1N1 vaccines.

In November 2009, Sinopharm had bagged the honor of ‘China’s Outstanding Corporate Citizenship’. Sinopharm Group develops, manufactures, distributes, and markets medicine and other healthcare products. The company manages factories, research laboratories, traditional Chinese medicine plantations, and marketing and distribution networks that extend throughout China. It also has 10 subsidiaries and a number of major joint ventures. The company also runs about a dozen retail pharmacy chains. Sinopharm Group, which has operations in Africa, France, Germany, Hong Kong, the US, and Vietnam, was formed in 1998.

The manufacturing of healthcare related products like prevention,treatment, diagnosis and nursing products, has taken Sinopharm to leading positions in several medical associations.

So far, Sinopharm has formed the distinctive pharmaceutical distribution and logistics business unit with Sinopharm Group (Holding), the medicinal retail business unit with GuoDa Pharmacy, the biopharm unit with the six major institutes of biological products, and the chemical pharmaceutical production unit with China National Pharmaceutical.

The 10 business units of the company support each other to form a complete pharmaceutical platform bringing in the economies of scale spurring the exponential growth of the business performance. From the year 2003 to 2009, the sales revenue, gross profit and total assets of Sinopharm grew at an annual average rate of 32 percent, 53 percent and 31 percent respectively.

Milestones 2009

• Signed a memorandum with Mitsubishi Corporation and Medipal Holdings for a comprehensive strategic alliance.
• Through this joint venture investment, Mitsubishi and Medipal plan to make inroads into China’s pharmaceutical distribution and wholesales business.

Related Articles:

APAC life science industry grows 3.4%, clocks $110 bn: BioSpectrum
BioSpectrum Asia Pacific Top 20 Companies:
Rank 1; Rank 2; Rank 3; Rank 4; Rank 5; Rank 6; Rank 7; Rank 8; Rank 9;
Rank 10;  Rank 11; Rank 12; Rank 13; Rank 14; Rank 15; Rank 16; Rank 17;
Rank 18; Rank 19; Rank 20
Country analysis: Australian companies step up investments
China: World's largest market exceeds growth forecast
India: Increased healthcare access drives market
 Singapore: Investment streams-in
Malaysia: Growth in-step with economic recovery
South Korea: All set for the next level of growth
Taiwan: Home to 14 of Asias fastest companies